Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy

Prostate

Volumn 74, Issue 16, 2014, Pages 1655-1662

  Zheng, Qizhi ^a   Peskoe, Sarah B ^b   Ribas, Judit ^a,d   Rafiqi, Fatema ^a   Kudrolli, Tarana ^a   Meeker, Alan K ^a,c   De Marzo, Angelo M ^a,c   Platz, Elizabeth A ^a,c   Lupold, Shawn E ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Universitat de Lleida Facultat de Medicina Sabadell   (Spain)

Author keywords

biochemical recurrence; microRNA; miR 141; miR 21; miR 221; prostate cancer

Indexed keywords

MICRORNA 141; MICRORNA 21; MICRORNA 221; MICRORNA; MIRN141 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRN221 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PILOT STUDY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; ADENOCARCINOMA; AGED; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; METABOLISM; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84921990624     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22883     Document Type: Article

References (48)

1. Fabian MR, Sonenberg N, Filipowicz W,. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351-379.
2. Kent OA, Mendell JT,. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25 (46): 6188-6196.
3. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR,. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834-838.
4. Lujambio A, Lowe SW,. The microcosmos of cancer. Nature 2012; 482 (7385): 347-355.
5. McDermott U, Downing JR, Stratton MR,. Genomics and the continuum of cancer care. N Engl J Med 2011; 364 (4): 340-350.
6. Cooperberg MR, Carroll PR, Klotz L,. Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 2011; 29 (27): 3669-3676.
7. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9-29.
8. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM,. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103 (7): 2257-2261.
9. Ozen M, Creighton CJ, Ozdemir M, Ittmann M,. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27 (12): 1788-1793.
10. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J,. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16 (3): 206-216.
11. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM,. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68 (15): 6162-6170.
12. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67 (13): 6130-6135.
13. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105 (30): 10513-10518.
14. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H,. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128 (3): 608-616.
15. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton JF, Carroll P, Blelloch R,. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011; 71 (2): 550-560.
16. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW,. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013; 73 (4): 346-354.
17. Amankwah EK, Anegbe E, Park H, Pow-Sang J, Hakam A, Park JY,. miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl 2013; 15 (2): 226-230.
18. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L, Seth A,. miR-221 is down-regulated in TMPRS S2: ERG fusion-positive prostate cancer. Anticancer Res 2011; 31 (2): 403-410.
19. Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Strobel P, Gessler M, Riedmiller H, Spahn M,. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 2014; 74 (9): 2591-2603.
20. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K,. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126 (5): 1166-1176.
21. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B,. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127 (2): 394-403.
22. Kang SG, Ha YR, Kim SJ, Kang SH, Park HS, Lee JG, Cheon J, Kim CH,. Do microRNA96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma ? Asian J Androl 2012; 14 (5): 752-757.
23. Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, Hu MM,. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 2012; 187 (4): 1466-1472.
24. Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, Jung K, Stephan C, Fleshner NE, Yousef GM,. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem 2013; 59 (11): 1595-1603.
25. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD,. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 2013; 109 (3): 641-650.
26. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, Isaacs WB, Platz EA,. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2012; 21 (10): 1774-1782.
27. Wang MH, Shugart YY, Cole SR, Platz EA,. A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 2009; 18 (3): 706-711.
28. Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ,. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011; 24 (11): 1511-1520.
29. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ,. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012; 25 (11): 1543-1549.
30. D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH,. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin Cancer Res 2010; 16 (23): 5908-5913.
31. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM,. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci USA 2012; 109 (37): 14977-14982.
32. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD,. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120 (5): 1046-1054.
33. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG,. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334 (4): 1351-1358.
34. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A,. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102 (52): 19075-19080.
35. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN,. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10 (3): 507-517.
36. Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS,. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate 2014; 74 (1): 61-69.
37. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GS, Kantoff PW,. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate 2012; 72 (10): 1093-1103.
38. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD, Butler LM,. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012; 131 (3): 652-661.
39. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U,. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011; 32 (3): 583-588.
40. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE,. miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69 (18): 7165-7169.
41. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW,. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71 (3): 326-331.
42. Krichevsky AM, Gabriely G,. miR-21: A small multi-faceted RNA. J Cell Mol Med 2009; 13 (1): 39-53.
43. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN,. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18 (3): 282-293.
44. Medina PP, Nolde M, Slack FJ,. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467 (7311): 86-90.
45. Li T, Li D, Sha J, Sun P, Huang Y,. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009; 383 (3): 280-285.
46. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, von Bergen M, Horn F, Brocke-Heidrich K,. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011; 30 (26): 2975-2985.
47. Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, Huang T, Sun LZ,. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 2013; 33 (31): 4097-4106.
48. Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Zhu YP, Xiao WJ, Ma CG,. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 2010; 31 (7): 867-873.